Frontiers in pediatrics · 2025
Case Report: A case of severe pulmonary hypertension combined with FBN1 mutation associated geleophysic dysplasia.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Ze-Yang, Cao Yuan, Yang Jie, He Xue-Hua, Liu Li-Ping, Yuan Yong-Hua
Аннотация
BACKGROUND: FBN1 gene mutation-associated geleophysic dysplasia (GD) leads to the formation of complex and refractory pulmonary hypertension (PH) through a multifactorial combination of precapillary factors, postcapillary factors, and respiratory pathology. However, clinical experience regarding the diagnosis and management of these patients remains limited.
CASE REPORT: The patient was admitted to the hospital with severe PH symptom. He exhibited typical facial features, severe disproportionate short stature, and was diagnosed with GD following the identification of a heterozygous mutation in exon 42 of the FBN1 gene via whole-exome sequencing. Pulmonary artery pressure was reduced after admission and treatment with treprostinil, but mitral stenosis progressively worsened. The patient was then treated with mitral valvuloplasty + atrial septal windowing at an outside hospital, the procedure was successful, but the patient could not be weaned from ECMO after the procedure.
CONCLUSION: This case expands our understanding of therapeutic strategies for PH associated with FBN1 mutation-related GD. Treprostinil may be effective in the treatment of these patients. Given the risk of progressive pulmonary disease, early surgical intervention for mitral valve pathology may be crucial for improving prognosis.
CASE REPORT: The patient was admitted to the hospital with severe PH symptom. He exhibited typical facial features, severe disproportionate short stature, and was diagnosed with GD following the identification of a heterozygous mutation in exon 42 of the FBN1 gene via whole-exome sequencing. Pulmonary artery pressure was reduced after admission and treatment with treprostinil, but mitral stenosis progressively worsened. The patient was then treated with mitral valvuloplasty + atrial septal windowing at an outside hospital, the procedure was successful, but the patient could not be weaned from ECMO after the procedure.
CONCLUSION: This case expands our understanding of therapeutic strategies for PH associated with FBN1 mutation-related GD. Treprostinil may be effective in the treatment of these patients. Given the risk of progressive pulmonary disease, early surgical intervention for mitral valve pathology may be crucial for improving prognosis.